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Abstract
Background: Granulosa cell tumors (GCT) are a rare ovarian neoplasm but prognosis is poor following recurrence.
Keratin intermediate filaments expressed in these tumors are a diagnostic marker, yet paradoxically, may also
constitute a target for therapeutic intervention. In the current study, we evaluated keratin 8/18 (K8/18) filament
expression as a mechanism of resistance to apoptosis in GCT, specifically focusing on regulation of the cell surface
death receptor, Fas (FAS).
Methods: The GCT cell line, KGN, was transiently transfected with siRNA to KRT8 and KRT18 to reduce K8/18
filament expression. Expression of K8/18, FAS, and apoptotic proteins (PARP, cleaved PARP) were evaluated by
fluorescence microscopy, flow cytometric analysis, and immunoblotting, respectively. The incidence of FAS-mediated
apoptosis in KGN cells was measured by caspase 3/7 activity. All experiments were performed independently three to
six times, using a fresh aliquot of KGN cells for each experiment. Quantitative data were analyzed by one- or two-way
analysis of variance (ANOVA), followed by a Tukey’s post-test for multiple comparisons; differences among means were
considered statistically significant at P < 0.05.
Results: Control cultures of KGN cells exhibited abundant K8/18 filament expression (~90 % of cells), and minimal
expression of FAS (<25 % of cells). These cells were resistant to FAS-activating antibody (FasAb)-induced apoptosis, as
determined by detection of cleaved PARP and measurement of caspase 3/7 activity. Conversely, siRNA-mediated
knock-down of K8/18 filament expression enhanced FAS expression (> 70 % of cells) and facilitated FasAb-induced
apoptosis, evident by increased caspase 3/7 activity (P < 0.05). Additional experiments revealed that inhibition of
protein synthesis, but not MEK1/2 or PI3K signaling, also prompted FasAb-induced apoptosis.
Conclusions: The results demonstrated that K8/18 filaments provide resistance to apoptosis in GCT by impairing FAS
expression. The abundance of keratin filaments in these cells and their role in apoptotic resistance provides a greater
mechanistic understanding of ovarian tumorgenicity, specifically GCT, as well as a clinically-relevant target for potential
therapeutic intervention.
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Background
Granulosa cell tumors (GCT) represent approximately
5 % of ovarian malignancies, yet constitute the most
prevalent sex cord-stromal ovarian neoplasms [1, 2].
Prognosis is favorable when detected early, but recurrent
GCT may be life-threatening. The rarity of these tumors
and their low potential for malignancy (i.e., slow growth
over a prolonged period) has reduced the urgency to
study and develop standard treatment regimens for these
neoplasms compared to other ovarian cancers. However,
GCT have a high rate of reappearance following resection
[2–4], and such recurrence often leads to late detection
and poor prognosis [5, 6]. Distinct from other ovarian
cancers, GCT are endocrine tumors [7]. High estrogen se-
cretion by GCT can lead to a variety of malignancies and
pathological states, including oligomenorrhea, hirsutism,
breast cancer, endometrial hyperplasia and adenocarcin-
oma [5, 8–10]. Additionally, GCT have many morpho-
logical and biochemical features akin to granulosa cells of
mature, preovulatory follicles (e.g., FSH-responsive and
steroid hormone production) [11–14].
Tumorigenicity of GCT is linked to a somatic mis-
sense mutation in the Forkhead Box L2 (FOXL2) gene
(c.402C→G; p.C134W). The mutation occurs in nearly
all adult-type GCT, yet is absent in juvenile GCT [14],
indicating the FOXL2 mutation is etiologically significant
in the development of adult GCT. The function of the
mutated FOXL2 is not fully understood, however it is
postulated to be a tumor suppressor. Overexpression of
FOXL2 induces expression of cell death receptors of the
Tumor Necrosis Factor Receptor Superfamily, particularly
the cell surface death receptor, Fas (FAS, also known as
TNFRSF6), which facilitates apoptosis of ovarian granu-
losa cells [15, 16]. In contrast, granulosa cells expressing
the FOXL2 C134W mutant lack these death receptors and
are resistant to apoptosis [16]. In spite of recent attempts
to develop therapeutic approaches using genetic manipu-
lation in mouse models [14, 17, 18] and transcriptomic
analysis to identify candidate driver genes [19, 20], rela-
tively little is known about selectively treating GCT.
Current treatment of GCT entails surgical resection of
the ovary and/or platinum-based chemotherapy - origin-
ally developed to specifically eliminate ovarian surface
epithelial (OSE) tumors [21]. However, ovarian carcin-
omas, including GCT and OSE tumors, share the com-
mon trait of expressing keratin intermediate filaments.
Keratin type I cytoskeletal 18 protein (K18, also known
as KRT18), in particular, is expressed in malignant cells
and is a diagnostic marker to delineate morphologic het-
erogeneity and neoplastic changes [22, 23]. Others argue
that the prevalence of intermediate filaments (i.e., kera-
tins, vimentin, and desmin) in GCT, as well as other
ovarian carcinomas, limits their value in differential
diagnosis among these groups [24].
The well-understood function of keratin intermediate
filaments is to provide stability and morphological integ-
rity to cells, yet in recent years a more dynamic role has
emerged. Structurally, keratin filaments are heterotetra-
mers of two type I and two type II keratins. Keratin 8/18
(K8/K18) intermediate filaments, for example, are com-
posed of keratin type II cytoskeletal 8 protein and type I
cytoskeletal 18 protein. Originally named for their mech-
anical stability, K8/18 filaments are “stress filaments”
that provide resistance against sheer stress; but they also
influence intracellular signaling mechanisms, counteract
physiological stressors, enhance wound healing, and pre-
vent apoptosis [25, 26]. Notably, K8/18-deficient epithelial
cells are sensitive to physiological stressors, including
cytokine-induced apoptosis [27–30]. In this context, K8/
18 filaments within cells associate with the tumor necrosis
factor receptor 1-associated death domain (TRADD) pro-
tein [31]. TRADD is a critical intracellular intermediate to
TNFR1-induced death signaling, which in turn interacts
with the Fas-Associated Death Domain (FADD) protein
[32]. By sequestering TRADD, K8/18 filaments potentially
attenuate and influence interactions between FAS, FADD
and other downstream apoptotic molecues, thus providing
resistance to cytokine-mediated apoptosis. In carcinoma-
derived cell lines (HeLa, HepG2, KLE), for example, dis-
ruption of K8/18 filament expression sensitizes the cells to
cisplatin-induced apoptosis by increasing FAS expression,
but also by decreasing the expression of the anti-apoptotic
protein, cellular FLICE inhibitory protein (c-FLIP, also
known as CFLAR) [33]. Based upon these observations,
keratin filaments constitute a plausible target for immune-
based approaches to cancer treatment, and might provide
an alternative to chemotherapy of GCT, in particular.
The granulosa-like KGN cell line, established from an
adult GCT, has provided insight about the molecular
and cellular features of GCT, along with potential vision
for treatment [34]. For instance, a recent investigation
revealed that, in contrast to OSE-derived cancers, inhib-
ition of NF-κB does not sensitize KGN cells to TRAIL-
or cisplatin-induced apoptosis [35]. Interestingly, human
granulosa cells and KGN cells share a similar resistance
to other forms of immune-mediated death, including
FAS-induced apoptosis [34, 36, 37]. Acknowledging that
K8/18 filament loss in other epithelial cell types leads to
increased FAS expression and enhanced vulnerability to
FAS-mediated apoptosis [28, 33], we hypothesized in the
current study, that K8/18 filaments in KGN cells provide
a similar mechanism of influence. Our objectives were
to first determine if KGN cells express K8/18 filaments
as seen in granulosa cells, GCT, and OSE tumors
[22, 23, 30] and then to identify the cellular mecha-
nism(s) by which K8/18 filaments potentially influence
resistance to FAS-mediated apoptosis. We observed that,
indeed, KGN cells express an abundance of K8/18
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filaments and genetic knockdown of K8/18 results in
enhanced expression of FAS and increased vulnerability to
FAS-mediated apoptosis.
Methods
Cells and culture conditions
The human granulosa cell tumor line, KGN, was gener-
ously provided by Dr. Fukuzawa (RIKEN Cell Bank,
Koyadai, Japan). KGN cells were maintained in DMEM/
F12 supplemented with 10 % FBS at 37 °C with 5 %
CO2, 95 % air and 95 % humidity. Cells were seeded in
multi-well plates, T25-flasks (Corning, Corning, NY) or
microchamber slides (Nunc, Rochester, NY) at a relative
seeding density of 5 × 104 cells/mL and grown to 70 %
confluency prior to treatment.
Immunofluorescent visualization of K8/K18 intermediate
filaments
The K18 protein is known to dimerize with K8 protein
to form K8/K18 filaments in ovarian steroidogenic cells
[30, 38]. KGN cells grown on coverslips were washed
with PBS, then fixed with ice-cold 4 % paraformaldehyde
(PFA) in PBS (pH 7.4) for 10 min. The fixed cells were
permeabilized for 10 min in 0.4 % Triton-X-100 in PBS.
Cells were washed and blocked with blocking buffer
(0.2 % Triton-X-100 in PBS with 10 % normal donkey
serum) for 30 min at room temperature. Cells were la-
beled with mouse anti-human K18-FITC-conjugated
antibody (CY90; Sigma-Aldrich, St. Louis, MO) diluted
1:100 in blocking buffer for 3.5 h at room temperature.
Cells were washed again and probed with Rhodamine
Phalloidin (1:1500, Life Technologies, Grand Island, NY)
and 4′,6-diamidino-2-phenylindole (DAPI; 30 nM) in
blocking buffer for 30 min at room temperature. For the
negative control, KGN cells were also exposed to a
mouse anti- human IgG-FITC-conjugated antibody
(Sigma-Aldrich, St. Louis, MO) diluted 1: 100 in blocking
buffer in place of the primary. The coverslips were washed
and then mounted with Fluoromount-G® (Southern
Biotechnology Associates, Inc, (Birmingham, AL). Im-
ages were captured using a Zeiss 710 Meta Confocal
Laser Scanning Microscope and analyzed using the
Zeiss Zen 2010 software (Carl Zeiss Microscopy, LLC,
Thornwood, NY, USA).
Flow cytometric quantification of FAS surface and K18
expression
Cultured cells were trypsinized using Cellgro 0.25 %
Trypsin-EDTA (Corning, Corning, NY) and fixed with
2 % PFA in microtubule-stabilizing buffer. For FAS
staining, the cells were stored in PFA; for K18 and total
FAS staining, the fixed cells were permeabilized in 70 %
ethanol. For antibody labeling, both types of cell prepa-
rations were washed with PBS + 0.1 % BSA, and then
either labeled overnight with mouse anti-human FAS
(CH11; EMD Millipore, Darmstadt, Germany) antibody
diluted to 20 μg/mL in 10 % normal goat serum (NGS) +
PBS + 1 % BSA, or for 1 h with mouse anti-human K18-
FITC-conjugated antibody (Sigma-Aldrich, St. Louis, MO)
diluted 1:100 in PBS + 1 % BSA. Separate fixed cell sus-
pensions were labeled with mouse anti-human IgG-FITC-
conjugated antibody (Sigma-Aldrich, St. Louis, MO) to
serve as the negative control. For FAS staining, the cells
were subsequently washed with PBS + 0.1 % BSA, and in-
cubated with Alexa Fluor® 488 (Life Technologies, Grand
Island, NY) diluted 1:200 in 10 % NGS + PBS + 1 % BSA.
All samples were washed with PBS + 0.1 % BSA and ana-
lyzed using a 4 color, dual laser FACS Calibur Flow Cyt-
ometer (BD Biosciences, San Jose, CA), quantifying 10,000
cells for each sample. Data were collected using CellQuest
software (BD Biosciences; San Jose, CA) and then ana-
lyzed using WinMDI (Joe Trotter; Purdue University,
West Lafayette, IN) to quantify FAS and keratin filament
expression.
Induction of FAS-mediated apoptosis
KGN cells were pretreated with cycloheximide (CHX;
0.25 μg/mL; Sigma-Aldrich, St. Louis, MO), the MEK1/2
inhibitor PD98059 (30 μM; Cell Signaling Technologies,
Danvers, MA) or the PI3K inhibitor Wortmannin (100
nM; EMD Millipore, Darmstadt, Germany) for 2 h in
serum-free culture medium. After pretreatment, the cells
were exposed to FAS-activating antibody (FasAb; 1 μg/
mL; clone CH11; EMD Millipore, Darmstadt, Germany),
or staurosporine (1 μM; MP Biomedical, Santa Ana, CA)
as a positive control, to induce apoptosis. The cells were
exposed to the above treatments for 8 and 24 h, at which
time caspase 3/7 activity was measured by the Caspase-
Glo® 3/7 Assay and cell viability was determined using
the CellTiter 96® AQueous One Solution Cell Prolifera-
tion Assay (MTS), respectively. Assays were conducted
according to the manufacturer’s instructions (Promega,
Madison, WI).
Immunoblot analysis for FAS, cFLIP, cleaved PARP and
β-actin
Nearly confluent cells from the above-described experi-
ments were washed with PBS and harvested in lysis buffer
(10 mM Tris–HCl; 1 mM EDTA; 1 mM EGTA; 100 mM
NaCl; 1 % Triton X-100; 0.5 % Nonidet P-40, pH 7.4)
containing a cocktail of kinase, protease and phosphatase
inhibitors (Sigma-Alrich, St. Louis, MO). Cells were
scraped, collected, sonicated and then resuspended in 2X
SDS loading buffer (100 mM Tris-Cl, pH 6.8 + 4 % SDS,
0.2 % bromophenol blue, 20 % glycerol, 200 mM DTT)
before denaturing at 95 °C for 5 min. Total cellular pro-
teins were separated by SDS-PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes (EMD
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Millipore,Darmstadt, Germany). Immunoblotting was
performed using antibodies to detect human cFLIP
(also known as CFLAR) (rabbit anti-human CFLAR;
Sigma Aldrich, St. Louis, MO) and human FAS (clone
C-20; Santa Cruz Biotechnology, Santa Cruz, CA).
The membranes were stripped and reprobed for
cleaved human poly ADP ribose polymerase (PARP)
(# 9542, Cell Signaling Technology, Danvers, MA), to
verify the apoptotic effect, and β-actin (clone AC-15;
Sigma Aldrich, St. Louis, MO) to ensure equivalent
protein loading.
Short interfering RNA (siRNA) knockdown of KRT8/18
gene transcription
KGN cells were transiently transfected with 10 pmol
siRNA constructs to KRT8 and KRT18 (Smartpool
Accell KRT8 and KRT18 siRNA; Dharmacon RNAi, GE
Healthcare, Lafayette, CO). Transfection was achieved
using Lipofectamine™ RNAiMAX in OptiMEM® Reduced
Serum Media for final 100 nM RNAi duplexes according
to the manufacturer’s instructions (Life Technoloies,
Grand Island, NY). Cells were grown to 70 % confluency
then switched to antibiotic-free DMEM/F12 + 10 % FBS
before siRNA- Lipofectamine™ duplexes were introduced.
The cells were also exposed to Lipofectamine™ and a non-
targeting siRNA (siCTL; Silencer® Select Negative Control
#1; Ambion Inc., Foster City, CA) as negative controls.
Knock-down of KRT8/18 expression was evaluated by im-
munofluorescence as described above.
Knock-down of KRT8/18 was also evaulated using an
in-cell western assay according to the manufacturer’s
instructions (LI-COR®, Lincoln, NE). Following a 72 h
exposure to siRNA, the cells were washed with PBS,
then fixed and permeabilized in 100 % MeOH. Detection
of K18 and β-Actin (internal control) expression was
achieved using an antibody cocktail of mouse anti-
human K18 (CY90; Sigma-Aldrich, St. Louis, MO) and
rabbit anti-human β-Actin (13E5, Cell Signaling Tech-
nolgy, Danvers, MA) followed by a secondary antibody
cocktail (goat anti-mouse IgG H + L DyLight 800 and
goat anti-rabbit IgG H + L DyLight 680, Cell Signaling
Technology, Danvers MA). The cells were imaged using
a LI-COR® Odyssey® Classic Infrared Imaging scanner.
Staining intensity for K18 was normalized to the staining
intensity for β-actin using the provided software.
Statistical analysis
All experiments were independently replicated three to
six times, using a fresh aliquot of KGN cells (passage
23-27) to initiate each experiment. Data were analyzed by
one- or two-way analysis of variance (ANOVA), followed
by a Tukey’s post-test for multiple comparisons; differ-
ences among means were considered statistically signifi-
cant at P < 0.05.
Results
Keratin and β-actin expression in KGN cells
Immunofluorescent staining of cultured KGN cells revealed
an abundance of K8/18 filament expression throughout the
cells (Fig. 1, green fluorescence). Both cytoplasmic and peri-
nuclear expression was evident, generally in parallel with β-
actin filament expression (Fig. 1, red fluorescence). Thus,
both K8/18 and β-actin filament expression are prominent
cytoskeletal components of cultured KGN cells.
Abundant K18 expression but minimal FAS expression on
KGN Cells
Flow cytometric analysis demonstrated ~ 91 % of KGN
cultured cells expressed K18 (Fig. 2a and c); consistent
with the abundance of keratin filament staining observed
by immunofluorescence (representative image shown in
Fig. 1). In contrast, only 24 % of the cells expressed FAS
(Fig. 2b and c), indicative of an overall inverse relationship
between K8/18 filament abundance and FAS expression.
Mean fluorescent intensity measures (an indication of
fluorescence per cell) were similarly high for keratin fila-
ment expression, but low for FAS expression (Fig. 2d).
Inhibition of protein synthesis sensitizes KGN cells to
FasAb-induced apoptosis
Exposure of KGN cells to FasAb for 8 h failed to induce
apoptosis, as measured by caspase 3/7 activity (Fig. 3). Con-
versely, pretreatment with cycloheximide (CHX, 0.25 μg/
ml), a protein synthesis inhibitor, augmented FasAb-induced
apoptosis (P < 0.05; Fig. 3). The effect was similar to that of
Staurosporine (1 μM), a chemotherapeutic agent used as a
positive control (P < 0.05, Fig. 3). Exposure of KGN cells to
CHX alone had no effect (P > 0.05). Similarly, disruption of
MEK1/2 (via PD98059; 30 μM) and PI3K (via Wortmannin;
100 nM) pro-survival pathways in KGN cells, failed to aug-
ment FasAb-induced apoptosis (data not shown).
Fig. 1 Representative images of immunofluorescent staining of K8/18
and β-actin filaments in cultured KGN cells. Cells were labeled with
mouse anti-human K18-FITC-conjugated antibody (keratin filaments,
green fluorescence), Phalloidin (β-actin filaments, red fluorescence),
DAPI (nuclei, blue fluorescence) or mouse anti-human IgG-FITC-
conjugated antibody (negative control). Individual and merged
images of fluorescence are shown
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FAS and cFLIP expression following FasAb-induced
apoptosis in KGN cells
Immunoblotting revealed no overt changes in FAS expres-
sion following exposure to CHX or FasAb in cultured
KGN cells (P > 0.05, Fig. 4a and b). Similarly, there was no
effect of CHX and/or FasAb on the expression of cFLIP
(P > 0.05, Fig. 4a and c). In contrast, effects of these treat-
ments were evident by the detection of PARP and cleaved
PARP (Fig. 4a and d), but only the combined treatment
led to a doubling (P < 0.05) of cleaved PARP (Fig. 4d). The
results confirmed the combined apoptotic effects of CHX
and FasAb as shown in Fig. 3.
Fig. 2 Flow cytometric analysis of K18 and FAS expression by cultured KGN cells. a, b Representative histograms and dot plots of fluorescence intensity
vs. number of recorded events for (a) K18 expression and (b) cell surface expression of FAS; c Percentage of KGN cell population (± SEM) stained positively
for K18 and FAS; d Mean fluorescence intensity (± SEM) of K18 and FAS expression by KGN cells. Bar graphs represent three independent experiments
Fig. 3 FasAb -induced apoptosis in cultured KGN cells, quantified by caspase 3/7 activity (RLU ± SEM) following inhibition of de novo protein synthesis.
The cultures were exposed to cycloheximide (0.25 μg/mL; CHX), for a total of 10 h and FasAb (1 μg/mL) during the last 8 h of culture. Staurosporine
treatment (1 μM) was included as the positive experimental control (n = 6 independent experiments; different letters denote differences, P < 0.05)
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siRNA knockdown of KRT8 and KRT18 enhances FasAb-
induced apoptosis of KGN cells
Knockdown of KRT8 and KRT18 in KGN cells (siRNA)
reduced keratin expression by 63 % as determined by in-
cell western (Fig. 5a and b) and 72 % by confocal imaging
(Fig. 5c). Subsequent experiments evaluated the effect of
KRT8 and KRT18 knockdown on FasAb-induced apop-
tosis in KGN cells. Treatment with Lipofectamine™, non-
targeting siRNA (siCTL) or KRT8/18 siRNA alone had no
effect on caspase 3/7 activity (P > 0.05, Fig. 6); however,
subsequent exposure to FasAb for 8 h resulted in a higher
incidence of apoptosis in KRT8/18 siRNA-treated cells
compared to controls (P < 0.05; Fig. 6). Of interest,
treatment with Lipofectamine™ and siCTL moderately
augmented the sensitivity of KGN cells to the apoptosis-
inducing effects of FasAb (Fig. 6).
Down-regulation of keratin filaments (siRNA) enhances
expression of FAS on KGN cells
Additional experiments revealed that siRNA-mediated
reduction of K8/18 expression enhanced expression of
FAS on the surface of KGN cells by 21 % as determined
by flow cytometry (P < 0.05; Fig. 7). By comparison, no
difference in total FAS expression (P > 0.05) was observed
among the treatment groups (Fig. 7). Of note, Lipofecta-
mine™ alone elevated the percentage of KGN cells that
expressed FAS on the cell surface (58 %, Fig. 7) compared
to that observed previously in non-treated controls (24 %,
Fig. 2). However, the effect did not overall enhance the
sensitivity of the cells to FasAb-induced apoptosis
(P > 0.05 Fig. 6).
Discussion
The current study is the first to demonstrate the expres-
sion of K8/18 filaments in KGN cells, a GCT-derived
cell line, which has clinical relevance to GCT in particu-
lar, but also to general ovarian malignancy. Acknowledg-
ing that these intermediate filaments help to counteract
physiological stressors [28, 39], we show that disrupting
K8/18 filament expression (via siRNA) in KGN cells
reverses resistance to FAS-mediated apoptosis by enhan-
cing FAS expression on the cell surface
Keratin filaments are typically expressed by cells of
epithelial origin [40]. Although the composition of
Fig. 4 Immunodetection of FAS, cFLIP, PARP, cleaved PARP and β-actin following exposure to the protein synthesis inhibitor CHX (0.25 μg/mL)
and FasAb (1 μg/mL) in KGN cells. a Representative immunoblot of FAS, cFLIP, PARP, cleaved PARP and β-actin following treatments; b Relative
expression of FAS normalized to β-actin (means ± SEM) following treatment; c Relative expression of cFLIP normalized to β-actin (means ± SEM)
following treatment; d Relative expression of cleaved PARP normalized to β-actin (Means ± SEM) following treatment. (n = 3 experiments, different
letters denote differences, P < 0.05)
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keratin filaments can be quite diverse and is predicated
by cell- and tissue-origin, previous reports document the
assembly of K18-containing filaments within ovarian-
derived tissues and tumors [26, 30, 38, 41]. Keratin fila-
ments constitute one type of intermediate filament
detectable within the ovary, particularly in granulosa
cells of the follicle during stages of growth and atresia
[30, 42], in luteal cells of the corpus luteum throughout
the luteal phase [30, 38, 43], and in oocytes of fetal and
adult ovaries [44, 45]. Other types of intermediate fila-
ments expressed within cells of the ovary include vimentin
and desmin [42, 46], which are of mesenchymal and myo-
genic origins, respectively [46]. Whether or not intermedi-
ate filaments other than K8/18 filaments impact FAS
expression or FAS-mediated apoptosis is unknown.
FAS-mediated apoptosis is characterized by the local-
ized secretion of Fas ligand, which then binds to FAS on
the target cell, inducing oligomerization of the ligand-
receptor complex. Oligomerization and internalization
of the ligand-receptor complex triggers association with
the cytoplasmic Fas-Associated Death Domain (FADD)
protein [47]. Interestingly, FADD is the common point
of convergence for both TNFR1-induced (via TRADD)
and Fas ligand-induced pathways of apoptosis in cells
[32]. In the current study, however, we focused only on
the FAS-mediated pathway of cell death. Subsequent to
activation, FADD facilitates the binding of pro-caspase 8
and the formation of the death inducing signaling complex
(DISC). Assembly of the DISC results in cleavage of pro-
caspase 8 to activate caspase 8, and initiates downstream
Fig. 5 Immunodetection of K18 and β-actin protein expression in KGN cells mock transfected (siCTL) or transfected with 100 nM siRNA to KRT8
and KRT18. a Representative in-cell western dual detection of K18 protein (green), β-actin protein (red), and combined (merged image-yellow)
following exposure to either Lipofectamine™ or equimolar concentrations of a non-targeting siRNA (siCTL) as controls, or 100 nM siRNA to KRT8/
18 (siKRT8/18). Diminished expression of K18 in the single and merged images was evident following 72 h exposure to siKRT8/18; b Quantification
of K18/β-actin expression compared to siCTL following siKRT8/18 transfection. The mean (± SEM) following treatment for three independent, replicate
experiments is depicted. c Representative image of immunofluorescent staining of K18 and actin filaments in cultured KGN cells. Keratin (K18) filament
expression stained with FITC (green); β-actin filament expression stained with Phalloidin (red); nuclei stained with DAPI (blue); and merged image of
FITC, Phalloidin and DAPI. Bar graph represents quantification of K18 fluorescence (mean relative light units, RLU ± SEM). (n = 6 independent images;
different letters denote differences, P < 0.05)
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events including the activation of caspase 3/7 enzymes that
ultimately trigger apoptosis of the cell [48].
In the context of GC and GCT, the expression of FAS
fundamentally determines the relative sensitivity of the
cells to FAS-mediated apoptosis. Overexpression of
wild-type, but not mutant FOXL2, in GC for example,
upregulates FAS expression and augments Fas ligand-
induced apoptosis [16]. Others report that granulosa and
KGN cells normally resistant to Fas ligand-induced
apoptosis become sensitized when pre-exposed to cyto-
kines that up-regulate FAS expression, such as interferon
gamma and tumor necrosis factor alpha [34, 37, 49]. In
the present study we show for the first time that siRNA-
mediated knockdown of K8/18 filaments in these cells also
increases FAS expression and enhances FasAb-induced
apoptosis. Consistent with the concept that FAS expres-
sion ultimately determines the sensitivity to FAS-mediated
apoptosis, we also report that treatment of KGN cells with
Lipofectamine™ increases trafficking of FAS to the cell
surface and enhances responsiveness to FasAb, albeit to a
lesser extent than the depletion of K8/18 filaments.
Inhibition of protein synthesis (via CHX) similarly en-
hances cell sensitivity to FasAb-induced apoptosis [36],
but does so ostensibly by impairing the synthesis of cyto-
plasmic and labile, anti-apoptotic proteins rather than
influencing FAS expresssion. In the current study, we
observed increased apoptosis of KGN cells (i.e., in-
creased caspase 3/7 activity and cleaved PARP expres-
sion) only after pretreating the cells with CHX for 2 h
and then exposing them to FasAb (Figs. 3 and 4). Con-
versely, treatment with CHX or FasAb alone failed to
induce apoptosis, and there was no effect of either treat-
ment, alone or in combination, on the total expression
of FAS or cFLIP (Fig. 4), a well-documented anti-
apoptotic protein [50]. It is unclear why in the current
study transient inhibition of protein synthesis failed to
reduce cFLIP expression, yet augmented FasAb-induced
apoptosis. Others have suggested that cFLIP plays an im-
portant role in preventing apoptosis in KGN cells [36, 51]
and that CHX inhibits cFLIP expression [36, 52]. One
explanation for the discrepancy in results between these
previous reports and the current study might be the con-
centration of CHX used to inhibit protein synthesis (5-
25 μg/mL in previous reports versus 0.25 μg/mL in this
study, respectively). Isoforms of cFLIP also exist [53–55],
which further complicates the interpretation of direct
comparisons among studies. For these reasons, we suggest
that additional investigation is needed to clarify the role of
cFLIP as well as other potential anti-apoptotic molecules
in KGN cells.
The activation of MAPK/ERK1/2 and PI3K/AKT sig-
naling pathways have been implicated in the prolifera-
tion of KGN cells [56]. In previous work, we determined
that inhibitors of these pro-survival signaling pathways
prevent TGFα-induced phosphorylation of ERK1/2 and
AKT in KGN cells [57], providing a potential role for
TGFα in GCT initiation, progression and metastasis.
However, inhibition of ERK1/2 phosphorylation has little
to no effect on cell cycle progression or proliferation of
Fig. 7 Measurement of the cell surface expression and total expression of FAS in KGN cells by flow cytometric analysis. The cells were analyzed
following siRNA transfection with Lipofectamine™, siCTL or siKRT8/18 (n = 6 experiments; different letters denote differences, P < 0.05)
Fig. 6 FasAb-induced apoptosis as measured by caspase 3/7 activity
(RLU ± SEM) following siRNA transfection with siCTL and siKRT8/18 in
cultured KGN cells (n = 3 experiments; different letters denote
differences, P < 0.05)
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KGN cells. Conversely, blocking AKT activation, or its
downstream target mTOR, impairs cell cycle progression
and prevent cell proliferation in cell culture [57] and in
vivo models of GCT [58]. Thus, the AKT pathway
appears more influential on the tumorigenic potential of
KGN cells than the ERK1/2 pathway, and this is consistent
with the identification of AKT1 as a driver gene of GCTs
[19]. In the present study, we observed that inhibiting
either the ERK1/2 or AKT pathway (via PD98059 and
Wortmannin, respectively) failed to augment the
apoptotic effects of FasAb, as suggested by other
models [59–61]. In the context of the present study,
keratin filaments are known to regulate cell cycle pro-
gression [62, 63]. Therefore, we speculate that these
filaments have the potential to modulate the effects
of cell signaling inhibitors on KGN cell proliferation
and apoptotic sensitivity.
The concept that keratin filaments influence the traf-
ficking of cytokine receptors, as demonstrated in the
current study, is a relatively new and unique attribute
ascribed to intermediate filaments. Inhibition of keratin
filament expression deems epithelial cells and carcinoma
cell lines more sensitive to FAS-mediated apoptosis via a
receptor mechanism [64, 65]. Additionally, expression of
keratin filaments within a lymph node metastatic carcin-
oma cell line impairs human leukocyte antigen (HLA)
class I receptor expression, enabling the cells to avoid
destruction by CD8+ cytotoxic lymphocytes [66]. Our
observations in which siRNA-mediated knockdown of
K8/18 filaments in KGN cells increased FAS expression
and enhanced sensitivity to FasAb-induced apoptosis is
consistent with evidence that shows knockdown of KRT18
increases FAS expression in both non-tumorigenic and
tumorigenic cells [28, 33]. The abundance of keratin fila-
ments in tumorigenic cells and their influence on meta-
static potential has generated considerable interest among
oncologists in recent years [67–69]. The current thinking
is that keratin filaments facilitate migration of cancer cells
in a manner separate from epithelial-mesenchymal transi-
tions. Yet, surprisingly, this role of keratin filaments in
cancer progression also renders some cell-types more sen-
sitive to cisplatin therapy [33]. Of relevance to GCT,
Woods and co-workers determined that KGN cells are
resistant to cisplatin and tumor necrosis factor-related
apoptosis inducing ligand [35, 70]. Unlike many other
types of cancer cells, however, the KGN cells remain
insensitive to these chemotherapeutic agents even after in-
hibition of NF-κB [35]. In the context of the current study,
it is evident that targeting keratin filament expression in
GCT and elevating FAS expression offers an alternative,
clinical approach to surgical resection or platinum-based
chemotherapy. However, therapeutic interventions that
impair keratin filament expression/organization and en-
hance the vulnerability of epithelial cancers to apoptosis
might also have the undesirable effect of augmenting
tumorigenic potential [33].
Conclusions
In conclusion, the abundance of keratin filaments in
KGN cells provides a clinically-relevant mechanism of
resistance to FAS-mediated apoptosis by impairing FAS
trafficking and possibly activating downstream anti-
apoptotic signaling molecules. Here, we provide evidence
that decreased expression of FAS at the cell surface, and
the presence/activation of labile protein(s) linked to kera-
tin filament expression, provide the means of apoptotic
resistance. The existence of keratin filaments in KGN cells
and their role in apoptotic resistance provides insight on
therapeutic strategies and tumorigenicity of cancers of
ovarian origin, specifically GCT and OSE tumors.
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